NSI-189
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
NSI-189 is a synthetic small-molecule neurogenic compound designed to stimulate neural stem cell proliferation in the hippocampus. Unlike conventional antidepressants, NSI-189 operates through a novel neurogenic mechanism — promoting the growth of new neurons rather than modulating neurotransmitter reuptake.
The compound has been investigated primarily in Phase 2 clinical trials for major depressive disorder, where it showed measurable increases in hippocampal volume and cognitive improvements in some measures. NSI-189 is not currently approved by any major regulator for therapeutic use and remains in the research phase.
How it works
NSI-189 promotes neurogenesis by stimulating neural stem cell proliferation in the hippocampus, the brain region critically involved in mood regulation and memory formation. In preclinical research, it has been shown to upregulate neurotrophic factors, particularly BDNF (brain-derived neurotrophic factor) and SCF (stem cell factor), which support the survival and differentiation of newly generated neurons.
This neurogenic mechanism represents a fundamentally different approach from traditional monoamine-based antidepressants, suggesting potential utility in situations where conventional treatments have shown limited benefit.
Reported benefits
- Stimulation of hippocampal neurogenesis (preclinical and Phase 2 data)
- Increased hippocampal volume measurable on imaging (Phase 2)
- Subjective cognitive improvements including memory and executive function (Phase 2 secondary outcomes)
- Potential antidepressant effects via neurogenic rather than monoamine pathways
These are reported and studied effects, not guaranteed outcomes. Human clinical evidence remains limited.
Considerations & side effects
Phase 2 clinical data is the most robust human evidence available for NSI-189, but large-scale, long-term safety studies have not been completed. The safety and efficacy profile in extended use is not well established.
Reported side effects in trial participants have been generally mild, though the complete adverse-event profile in diverse populations is not fully characterized. NSI-189 is not a substitute for evaluation and treatment by a qualified mental health professional.
Frequently asked
What is NSI-189?
NSI-189 is a small-molecule neurogenic compound developed by Neuralstem Inc. to stimulate the proliferation of neural stem cells in the hippocampus, with a different mechanism than traditional antidepressants.
Is NSI-189 FDA-approved?
No. NSI-189 is not FDA-approved for depression or any psychiatric indication in the United States. It received Orphan Drug Designation for Angelman Syndrome in 2026 but is sold for research purposes only.
How does NSI-189 differ from traditional antidepressants?
Traditional antidepressants target monoamine systems (serotonin, norepinephrine). NSI-189 instead promotes neurogenesis and upregulates neurotrophic factors like BDNF and SCF, representing an independent mechanism of action.
What did the Phase 2 trial show?
The Phase 2 study in major depression showed the 40 mg dose produced significantly greater subjective symptom reduction and cognitive improvements compared to placebo, with observed hippocampal volume increases of approximately 2.4%. However, the trial did not meet its primary efficacy endpoint on clinician-rated depression scales.
Is the safety profile established?
NSI-189 has been studied in clinical trials, but long-term human safety data is limited. It is not a substitute for evaluation and treatment by a qualified clinician.
References
Related compounds
Standardized neuropeptide preparation with neurotrophic and neuroprotective properties. Used clinically in 50+ countries for stroke recovery, traumatic brain injury, and dementia treatment.
An oral Khavinson peptide bioregulator (peptide complex A-5) derived from calf brain tissue, targeting the central nervous system. Taken in capsule courses to support cognitive function and neuronal health.
AEDP tetrapeptide brain cortex bioregulator. Supports neuroprotection, cognitive function, and nerve regeneration through epigenetic regulation.